U0750
尿嘧啶
≥99.0%, synthetic (organic), powder
别名:
2,4(1H,3H)-嘧啶二酮, 2,4-二羟基嘧啶, 灭胞素
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C4H4N2O2
化学文摘社编号:
分子量:
112.09
NACRES:
NA.51
PubChem Substance ID:
UNSPSC Code:
41106305
EC Number:
200-621-9
MDL number:
Beilstein/REAXYS Number:
507828
Assay:
≥99.0%
Biological source:
synthetic (organic)
Form:
powder
Solubility:
1 M NaOH: 50 mg/mL, clear to hazy, colorless to faint yellow or tan
产品名称
尿嘧啶, ≥99.0%
biological source
synthetic (organic)
Quality Level
assay
≥99.0%
form
powder
mp
>300 °C (lit.)
solubility
1 M NaOH: 50 mg/mL, clear to hazy, colorless to faint yellow or tan
SMILES string
O=C1NC=CC(=O)N1
InChI
1S/C4H4N2O2/c7-3-1-2-5-4(8)6-3/h1-2H,(H2,5,6,7,8)
InChI key
ISAKRJDGNUQOIC-UHFFFAOYSA-N
General description
尿嘧啶属于嘧啶碱基家族。它是天然存在的，是RNA重要而活跃的一部分。
Application
尿嘧啶已用作：
- 核苷酸标准品，以通过高效液相色谱法测定DNA甲基化
- 合成定义培养基组分，用于培养酿酒酵母及其菌株
- 用于培养芽孢杆菌的氨基酸补充物的组分
Biochem/physiol Actions
尿嘧啶及其衍生物在合成癌症、病毒感染、常染色体隐性遗传病、甲状腺和糖尿病药物的药物化学中不可或缺。
Still not finding the right product?
Explore all of our products under 尿嘧啶
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
商品
A shortened review of fundamentals of Porous Graphitic Carbon (PGC) materials. What they are and how do they work as a stationary phase material in HPLC?.
Hiroki Okada et al.
STAR protocols, 2(3), 100733-100733 (2021-08-31)
Microscopy-based analysis of protein accumulation at a given subcellular location in real time provides invaluable insights into the function of a protein in a specific process. Here, we describe a detailed protocol for determining protein accumulation kinetics at the division
Sandra M Carvalho et al.
PloS one, 8(3), e58492-e58492 (2013-03-19)
Links between carbohydrate metabolism and virulence in Streptococcus pneumoniae have been recurrently established. To investigate these links further we developed a chemically defined medium (CDM) and standardized growth conditions that allowed for high growth yields of the related pneumococcal strains
William B White et al.
The New England journal of medicine, 369(14), 1327-1335 (2013-09-03)
To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with alogliptin, a new
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| U0750-1KG | 04061826746004 |
| U0750-25G | 04061835522316 |
| U0750-100G | 04061837403828 |
| U0750-500G | 04061837403835 |
| U0750-5G | 04061835559428 |